{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-26-000003","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.922766+00:00","generated_at":"2026-05-16T10:48:42.571916+00:00","sec_items":["7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Emergent BioSolutions voluntarily prepays $100M of term loan; total debt reduced by $275M since 2023","bullets":["Voluntary prepayment of $100M on term loan using cash on hand in late December 2025.","Pro forma gross debt reduced to $593M, a 32% decline from $868M since the transformation plan began in 2023.","CEO Joe Papa says the prepayment improves financial flexibility and supports long-term growth initiatives.","Company to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-26-000003","json":"https://secwatch.observer/filing/0001367644-26-000003.json","markdown":"https://secwatch.observer/filing/0001367644-26-000003.md","text":"https://secwatch.observer/filing/0001367644-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000003/0001367644-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000003/ebs-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:48:42.571916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}